Medtronic clears spin-off milestone, diabetes IPO plans keep the stock in focus

By Stefan Krüger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 15:00.

Medtronic plc (IE00BTN1Y115) continues to work toward the separation of its diabetes business Minimed into a standalone listed company. The planned Minimed IPO on the NYSE with an issue volume of up to $784 million marks a strategic turning point for the healthcare group, as reported by BioWorld in February 2026. BioWorld coverage of the Minimed IPO plans

What the spin-off entails

According to the February 24, 2026 article in BioWorld, Minimed Group Inc., Medtronic’s diabetes unit, filed for an IPO seeking to raise up to $784 million in gross proceeds. The BioWorld report on Minimed states that Medtronic had disclosed the spin-off plan in May 2025, with a targeted completion timeframe of roughly 18 months from that announcement.

The diabetes unit houses Medtronic’s insulin pumps and continuous glucose monitoring solutions, and is being prepared as an independent entity to sharpen strategic focus on the distinct regulatory and commercial dynamics of diabetes technology. BioWorld notes that the separation should allow Minimed to pursue its own capital allocation and partnership strategy, separate from Medtronic’s broader portfolio. Details on Minimed’s planned listing

Long-term strategy and portfolio focus

Medtronic’s move to spin off Minimed fits a broader pattern of portfolio streamlining among large medical technology groups such as Abbott and Johnson & Johnson, where separate focused entities have been created for consumer or specialty segments. In Medtronic’s case, the retained company will concentrate more clearly on cardiovascular, neuroscience and surgical technologies, while diabetes care is ringfenced in Minimed.

The company has highlighted in prior communications that separating the diabetes business can improve capital allocation discipline and increase transparency for investors who want targeted exposure to diabetes technology versus Medtronic’s diversified medtech operations. The targeted 18-month timeline from the May 2025 announcement implies that the separation should be approaching its planned time window, which keeps the transaction relevant for medium-term stock assessments.

The product behind the stock

One of Medtronic’s representative products is the MiniMed insulin pump system, which forms a core part of its diabetes portfolio and is included in the Minimed business. The system combines programmable insulin delivery with sensor-based glucose monitoring to support tighter glycemic control for patients with type 1 diabetes, and it is marketed in major regions including North America and Europe.

Where the stock trades today

Medtronic shares (IE00BTN1Y115) trade on the NYSE under the ticker MDT; recent indicative data from MarketBeat shows a closing price of $80.94 on June 26, 2026, with a small move in extended trading to around $81.00 in the early hours of June 27, 2026. MarketBeat’s latest MDT quote and trading range

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to engage in any securities transaction. All data are based on sources believed to be reliable at the time of publication, but accuracy and completeness cannot be guaranteed.